Literature DB >> 19158416

Synaptic retrogenesis and amyloid-beta in Alzheimer's disease.

Pontus Wasling1, Jonny Daborg, Ilse Riebe, My Andersson, Erik Portelius, Kaj Blennow, Eric Hanse, Henrik Zetterberg.   

Abstract

Pathological hallmarks of Alzheimer's disease (AD) include synaptic and neuronal degeneration and the presence of extracellular deposits of amyloid-beta (Abeta) in senile plaques in the cerebral cortex. Although these brain lesions may be seen also in aged non-demented individuals, the increase in brain Abeta is believed by many to represent the earliest event in the disease process. Accumulating evidence suggests that Abeta, which is highly conserved by evolution, may have an important physiological role in synapse elimination during brain development. An intriguing idea is that this putative function can become pathogenic if activated in the aging brain. Here, we review the literature on the possible physiological roles of Abeta and its precursor protein AbetaPP during development with special focus on electrophysiological findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158416     DOI: 10.3233/JAD-2009-0918

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  12 in total

Review 1.  Herpes simplex virus type 1 persists in the aged brain through hypothetical expression of accessory genes.

Authors:  Isamu Mori
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory.

Authors:  Julio J Ramirez; Winona E Poulton; Erik Knelson; Cole Barton; Michael A King; Ronald L Klein
Journal:  Behav Brain Res       Date:  2010-08-19       Impact factor: 3.332

Review 3.  AMPA-silent synapses in brain development and pathology.

Authors:  Eric Hanse; Henrik Seth; Ilse Riebe
Journal:  Nat Rev Neurosci       Date:  2013-11-08       Impact factor: 34.870

Review 4.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

Review 5.  Amyloid-β as a modulator of synaptic plasticity.

Authors:  Mordhwaj S Parihar; Gregory J Brewer
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  The microtubule-associated protein 1A (MAP1A) is an early molecular target of soluble Aβ-peptide.

Authors:  C Clemmensen; S Aznar; G M Knudsen; A B Klein
Journal:  Cell Mol Neurobiol       Date:  2012-01-18       Impact factor: 5.046

7.  Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease.

Authors:  Erik Portelius; Ulf Andreasson; John M Ringman; Katharina Buerger; Jonny Daborg; Peder Buchhave; Oskar Hansson; Andreas Harmsen; Mikael K Gustavsson; Eric Hanse; Douglas Galasko; Harald Hampel; Kaj Blennow; Henrik Zetterberg
Journal:  Mol Neurodegener       Date:  2010-01-14       Impact factor: 14.195

Review 8.  Can BACE1 inhibition mitigate early axonal pathology in neurological diseases?

Authors:  Xiao-Xin Yan; Chao Ma; Wei-Ping Gai; Huaibin Cai; Xue-Gang Luo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 9.  Aβ toxicity in Alzheimer's disease.

Authors:  Virve Cavallucci; Marcello D'Amelio; Francesco Cecconi
Journal:  Mol Neurobiol       Date:  2012-03-14       Impact factor: 5.590

Review 10.  Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease.

Authors:  I A Clark; B Vissel
Journal:  Br J Pharmacol       Date:  2015-06-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.